Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis

By Sancricca Cristina  

Neurological Sciences, Vol. 32, Iss. 5, 2011-10 ,pp. : 841-847

Springer Publishing Company

Access to resources Recommend Favorite

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

By Nogalska Anna  

Acta Neuropathologica, Vol. 118, Iss. 3, 2009-09 ,pp. : 407-413

Springer Publishing Company

Access to resources Recommend Favorite

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

By Hirst C.   Pace A.   Pickersgill T.   Jones R.   McLean B.   Zajicek J.   Scolding N.   Robertson N.  

Journal of Neurology, Vol. 255, Iss. 2, 2008-02 ,pp. : 231-238

Springer Publishing Company

Access to resources Recommend Favorite

Update on sporadic inclusion body myositis

By Hohlfeld Reinhard  

Brain, Vol. 134, Iss. 11, 2011-11 ,pp. : 3141-3145

Oxford University Press

Access to resources Recommend Favorite

Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers

By Cacciottolo Mafalda   Nogalska Anna   D’Agostino Carla   Engel W.   Askanas Valerie  

Acta Neuropathologica, Vol. 126, Iss. 5, 2013-11 ,pp. : 781-783

Springer Publishing Company

Access to resources Recommend Favorite